Heart Failure Treatment and Management

SEP 4, 2026 · JOURNAL ARTICLE

Sex Differences in HFpEF: Mechanisms, Manifestations, and Therapeutic Target Identification

International Journal of Drug Discovery and Pharmacology

A narrative review synthesizing mechanistic concepts and observational patterns in sex differences in HFpEF, raising questions about pathophysiology rather than presenting empirical evidence of efficacy or harm.

AUG 8, 2026 · JOURNAL ARTICLE

Type 2 Diabetes in Heart Failure with Preserved and Mildly-Reduced Ejection Fraction: Insights from the REDUCE-LAP-HF II trial

Esc Heart Failure

Rigorous secondary analysis of a prospectively phenotyped cohort with invasive hemodynamic assessment, multivariable adjustment, and hard clinical endpoints over 4-year follow-up demonstrates T2DM's independent association with adverse cardiac remodeling and clinical outcomes in HFpEF/HFmrEF.

AUG 7, 2026 · JOURNAL ARTICLE

Contemporary medical therapy for heart failure with mildly reduced or preserved ejection fraction

Heart Failure Reviews

A narrative review synthesizing evidence from multiple RCTs to support contemporary treatment recommendations for HFmrEF and HFpEF, reflecting current European and American guideline positions.

AUG 3, 2026 · JOURNAL ARTICLE

SGLT2 Inhibitors in the Modern Cardiology Era: Mechanisms, Outcomes, and Clinical Applications

Cardiology in Review

A narrative review synthesizing mechanisms and trial evidence for SGLT2 inhibitors across heart failure and CKD, positioning them as foundational therapies; evidence quality varies by outcome and lacks quantified effect sizes.

AUG 1, 2026 · JOURNAL ARTICLE

Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure (TARTAN-HF)

Journal of the American College of Cardiology

Well-designed RCT with clear primary endpoint showing natriuretic peptide screening identifies unrecognized HF in diabetes at high frequency with robust effect size, though clinical outcomes and longer-term follow-up remain unreported.

JUL 28, 2026 · JOURNAL ARTICLE

Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study

The Lancet

Phase 3 RCT demonstrates ralinepag significantly reduces clinical worsening in PAH (HR 0.45, p<0.0001) versus placebo in 687 patients with contemporary background therapy, with acceptable safety profile supporting clinical use.

JUL 15, 2026 · JOURNAL ARTICLE

A NETwork meta-analysis with COST-effectiveness evaluation of pharmacological treatments for heart failure with reduced ejection fraction: NET-COST-HFrEF

European Journal of Heart Failure

Network meta-analysis of 47 RCTs with 75,978 patients synthesizing efficacy and cost-effectiveness data across multiple healthcare systems, demonstrating quadruple therapy as superior strategy with quantified health economic outcomes.

JUL 11, 2026 · JOURNAL ARTICLE

Safety and efficacy of DOACs in clinically complex phenotypes of patients with atrial fibrillation: focus on frailty, multimorbidity and polypharmacy

Expert Opinion on Drug Safety

A narrative review synthesizing evidence on DOAC safety and efficacy in complex AF phenotypes, offering expert recommendations for individualized care rather than reporting a single original empirical result.